Summary:
Assesment of Safety, Tolerability and Pharmacodynamic Effects of LY2886721 in patients with Mild Cognitive Impairment due to Alzheimer's Disease or Mild Alzheimer's Disease. Phase 2, parallel, randomized, placebo controlled, double-blind study comparing daily dosing of LY288671 to placebo over a 26-week treatment of MCI due to AD or mild AD.
Qualified Participants Must:
Present with Mild Cognitive Impairment due to AD or mild AD.
Be at least 55 years of age
Have a reliable caregiver
Be able to speak, read, write and understand English
Qualified Participants May Receive:
Two different dose levels to placebo over a 26 week period. Followed with a 2-week follow up.